Printer Friendly

UPJOHN WELCOMES FDA ADVISORY COMMITTEE MEETING ON HALCION

 UPJOHN WELCOMES FDA ADVISORY COMMITTEE MEETING ON HALCION
 KALAMAZOO, Mich., April 21 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) said today that it welcomes the opportunity to participate in an upcoming U.S. Food and Drug Administration (FDA) Advisory Committee meeting on Halcion Tablets, Upjohn's prescription sleeping medication. The FDA has scheduled a meeting of its Psychopharmacological Drug Products Advisory Committee on May 18 to discuss scientific data related to Halcion.
 Theodore Cooper, M.D., Ph.D., Upjohn's chairman of the board and chief executive officer, said, "We're pleased that the FDA has requested its Advisory Committee to look at Halcion in a scientific forum. We have, in fact, suggested such a meeting to the FDA over the past several months. We plan to present in considerable detail scientific evidence surrounding the safety and efficacy of this product."
 "The regulatory agency is the appropriate place to discuss the safety and efficacy of Halcion," Cooper continued. "It's Upjohn's policy and philosophy to cooperate with these authorities throughout the world."
 In November 1991, Upjohn announced a patient package insert and a smaller package for Halcion, as well as modifying the product's labeling. The FDA wrote letters to manufacturers of four other benzodiazepine sleeping medications in December, requesting each of them to make packaging and labelling changes similar to those initiated by Upjohn. In addition, the European Community's Committee for Propriety Medicinal Products (CPMP) is reviewing the safety profiles of a number of sleeping medications. According to Cooper, "These are appropriate actions. Our first concern is for the patients. For their benefit, it's vital that all of these important products be used correctly."
 The May 18 Advisory Committee meeting will be the third such FDA activity in regard to Halcion. Previous committees met in 1978 and in 1989.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 4/21/92
 /CONTACT: Kaye P. Bennett of The Upjohn Company, 616-323-4223/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU:


JG -- DE012 -- 0565 04/21/92 11:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1992
Words:367
Previous Article:METROPHONE'S NEW EMERGENCY NUMBER KICKS OFF CELLULAR SAFETY PROGRAM
Next Article:CHEMICAL FINANCIAL CORPORATION ANNOUNCES FIRST-QUARTER OPERATING RESULTS


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
UPJOHN ENDORSES FDA ADVISORY COMMITTEE RECOMMENDATIONS ON HALCION
ADVISORY COMMISSION RECOMMENDS HALCION RETURN TO U.K. MARKET
FDA CONCLUDES HALCION INVESTIGATION
FINLAND RETURNS HALCION TO THE MARKET
UPJOHN RESPONDS TO WOLFE FDA LETTER
UPJOHN WINS HOUSTON HALCION CASE
UPJOHN WINS MASSACHUSETTS HALCION CASE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters